more

Bausch Health (BHC)

(Delayed Data from NYSE)

$8.16 USD

-0.20 (-2.39%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $8.16 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum A VGM

Industry Rank:

Bottom 37% (157 out of 250)

Industry: Medical - Generic Drugs

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why Is Bausch (BHC) Up 8.3% Since Last Earnings Report?

by Zacks Equity Research Published on March 22,2019

Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BHCNegative Net Change

Is Bausch Health Companies (BHC) a Great Stock for Value Investors?

by Zacks Equity Research Published on March 11,2019

Is Bausch Health Companies (BHC) a great pick from the value investor's perspective right now? Read on to know more.

BHCNegative Net Change

Aerie (AERI) Q4 Earnings Miss, Rhopressa Gains Traction

by Zacks Equity Research Published on February 26,2019

Aerie (AERI) reports wider-than-expected Q4 loss. Nevertheless, Rhopressa's sales beat estimates as demand picks up.

biotechs

Bausch (BHC) Q4 Earnings Beat Estimates, Revenues Down Y/Y

by Zacks Equity Research Published on February 21,2019

Bausch (BHC) Q4 earnings and revenues surpass estimates. However, guidance for 2019 is not impressive.

biotechs

Bausch Health (BHC) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research Published on February 20,2019

Bausch (BHC) delivered earnings and revenue surprises of 19.32% and 1.33%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

BHCNegative Net Change

What's in the Cards for Bausch Health (BHC) Q4 Earnings?

by Zacks Equity Research Published on February 15,2019

Investors are looking forward to Salix and Bausch+Lomb's performance, and other pipeline updates when Bausch (BHC) reports Q4 results on Feb 20.

pharmaceuticals

Earnings Preview: Bausch Health (BHC) Q4 Earnings Expected to Decline

by Zacks Equity Research Published on February 13,2019

Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BHCNegative Net Change

Bausch (BHC) Upgraded to Strong Buy: Here's Why

by Zacks Equity Research Published on February 05,2019

Bausch (BHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

BHCNegative Net Change

New Strong Buy Stocks for February 5th

by Tirthankar Chakraborty Published on February 05,2019

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday

airlines

Alexion (ALXN) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research Published on January 31,2019

Alexion's key drug like Soliris should drive growth in the fourth quarter of 2018.

biotechs

Is Bausch Health (BHC) Stock Undervalued Right Now?

by Zacks Equity Research Published on January 31,2019

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

BHCNegative Net Change

Has Bausch Health Cos (BHC) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research Published on January 29,2019

Is (BHC) Outperforming Other Medical Stocks This Year?

BHCNegative Net Change

Dr. Reddy's (RDY) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research Published on January 28,2019

Dr. Reddy's has launched few generics which should add to revenues of the company when the company releases its third-quarter fiscal 2019 results.

pharmaceuticals

Why Bausch (BHC) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research Published on January 23,2019

Bausch (BHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.